Xu W.,General Hospital of Guangzhou Military Command |
Qian Y.,General Hospital of Guangzhou Military Command |
Zhao L.,Guangzhou First Municipal Hospital
International Journal of Clinical and Experimental Medicine | Year: 2015
The Angiotensin-converting enzyme (ACE) I/D polymorphism has been indicated to be correlated with peripheral neuropathy (PN) susceptibility, but study results are still debatable. Thus, a meta-analysis was conducted. Databases including PubMed, Embase and CNKI were searched. Data were extracted and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated. Eight studies with 1430 cases and 1873 controls were included in this meta-analysis. The association between ACE I/D polymorphism and PN risk was significant (OR = 1.25; 95% CI 1.05-1.48; P = 0.01). When stratified by ethnicity, the significantly increased PN risk was observed in Caucasians (OR = 1.24; 95% CI 1.05-1.47; P = 0.01). In conclusion, this meta-analysis suggested that ACE I/D polymorphism was a risk factor for PN. © 2015, E-Century Publishing Corporation. All rights reserved.
Zhang M.,Guangzhou First Municipal Hospital |
Zeng J.,Guangzhou First Municipal Hospital |
Zhong W.,Guangzhou First Municipal Hospital |
He W.,Guangzhou First Municipal Hospital |
And 2 more authors.
Cancer Research and Clinic | Year: 2015
Objective: To evaluate the level changes of serum WASP-family verprolin homologous protein-1 (WAVE1) and vascular endothelial growth factor-C (VEGF-C) and their clinical significance in patients with advanced non-small lung cancer (NSCLC) before and after chemotherapy. Methods: Serum WAVE1 and VEGF-C were measured in 43 patients with advanced NSCLC by ELISA, and the results were compared with 43 healthy volunteers. Results: The levels of serum WAVE1 and VEGF-C before chemotherapy in patients group were (0.573 ±0.082) ng/ml and (947.3 ±125.4) pg/ml respectively, while in healthy volunteers group, they were (0.256±0.064) ng/ml and (425.5±110.1) pg/ml respectively, which suggested that before chemotherapy the levels of serum WAVE1 and VEGF-C in NSCLC group were significantly higher than those of in the control (P < 0.05). The serum levels of WAVE1 and VEGF-C in advanced NSCLC patients were closely related to lymph node metastasis status and distant metastasis status (P < 0.05), but not to the gender, age, tumor length, histology type, differentiation grade and C-TNM stage (P > 0.05). The serum WAVE1 and VEGF-C levels of the effective treatment group was (0.290±0.037) ng/ml and (596.1±127.5) pg/ml after chemotherapy respectively, which decreased obviously compared with the group before chemotherapy which levels were (0.517±0.051) ng/ml and (964.6±100.3) pg/ml (both P < 0.05). But the serum WAVE1 and VEGF-C levels of the ineffective treatment group were (0.547 ±0.065) ng/ml and (957.0±111.2) pg/ml after treatment, which had no difference compared with the group before chemotherapy which levels were (0.517±0.051) ng/ml and (964.6±100.3) pg/ml (both P > 0.05). Furthermore, statistically significant relationship was found between the serum WAVE1 and the VEGF-C levels (r = 0.331, r = 0.540, both P < 0.05). Conclusion Serum WAVE1 and VEGF-C may be used as indicators for prediction of the efficacy of chemotherapy in patients with advanced NSCLC.